Current Allergy and Asthma Reports

, Volume 11, Issue 4, pp 300–308

New Therapeutics in C1INH Deficiency: A Review of Recent Studies and Advances


DOI: 10.1007/s11882-011-0203-x

Cite this article as:
Parikh, N. & Riedl, M.A. Curr Allergy Asthma Rep (2011) 11: 300. doi:10.1007/s11882-011-0203-x


Hereditary angioedema (HAE) is a genetic condition causing a significant burden of illness for affected individuals. Episodes of angioedema involving the skin, gastrointestinal tract, as well as the larynx and oropharynx are often unpredictable and cause significant morbidity and mortality. Isolation of the underlying protein deficiency, specifically the serine protease C1 inhibitor, and further description of its role in multiple physiologic cascades has led to the development of several specific therapies for HAE. This report provides a brief overview of HAE but focuses primarily on reviewing recently published clinical studies of therapeutics developed for medical management of the condition.


Hereditary angioedemaC1INH deficiencyEcallantideIcatibantC1 inhibitor proteinBradykininKallikreinClinical studiesTreatmentTherapeutics

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Clinical Immunology and Allergy, Department of MedicineUCLA David Geffen School of MedicineLos AngelesUSA